NEW YORK — Startup Deep Longevity said on Tuesday that it has closed a Series A round of financing and formed a partnership with genome sequencing company Human Longevity.
Spun out of Insilico Medicine in January, Deep Longevity is developing artificial intelligence-based systems to track aging based on a variety of molecular, cellular, and other biomarkers and datapoints. Its offerings include so-called aging clocks designed to provide measures of biological age.
Deep Longevity raised "a few million" dollars through the Series A, according to a spokesperson for the Hong Kong-based company who declined to provide an exact figure. The round was led by ETP Ventures and Human Longevity and Performance Impact Venture Fund, and included Bold Capital Partners, Longevity Vision Fund, Formic Ventures, and LongeVC.
Under the terms of their collaboration, Deep Longevity will make its technologies available through Human Longevity, which is using next-generation sequencing and machine learning to build a genomic and phenotypic database for personalized medicine.
Additional terms were not disclosed.
Earlier this year, San Diego-based Human Longevity sold its oncology division to NeoGenomics for $37 million in cash.